Ask AI
ProCE Banner Activity

CME

Evolving Role of TROP-2–Directed ADCs as First-line Therapy in TNBC

Text Module

Read this text module to learn about recent advances in the treatment of metastatic triple-negative breast cancer (mTNBC), with a focus on the evolving role of sacituzumab govitecan and datopotamab deruxtecan as TROP-2–directed antibody–drug conjugates (ADCs) in the first-line setting. Learners will examine the clinical evidence supporting newly approved therapies, compare key phase III trial designs and efficacy and safety data, and explore practical considerations for treatment selection, supportive care planning, and integration of these agents into contemporary treatment algorithms. The activity also highlights emerging ADCs, targeted therapies, and combination strategies that may further expand treatment options for patients with mTNBC.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: August 28, 2026

Expiration: February 27, 2027

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity has been designed to meet the educational needs of oncologists and other healthcare professionals involved in the management of patients with triple-negative breast cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Breast Cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop treatment plans that incorporate TROP-2-directed ADCs for patients with mTNBC aligned with the latest evidence and guideline recommendations for TNBC

Financial Disclosures

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Ana C. Garrido-Castro, MD: researcher (paid to institution): 4D Path, AstraZeneca, Bicycle, BioNTech, Biovica, Bristol Myers Squibb, Case45, Daiichi Sankyo, Foundation Medicine, Gilead, Merck, Novartis, Precede Biosciences, Reveal Genomics, Zenith Epigenetics; consultant/advisor/speaker: AstraZeneca, Bicycle, BioNTech, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, Merck, Novartis, Pfizer, Roche/Genentech, TD Cowen; other financial or material support: AstraZeneca, Daiichi Sankyo, Gilead, Merck, Novartis, Pfizer, Roche/Genentech, Stemline.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 28, 2026, through February 27, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.